Patents Assigned to LINEAGEN, INC.
-
Patent number: 9945872Abstract: Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.Type: GrantFiled: July 3, 2012Date of Patent: April 17, 2018Assignee: Lineagen, Inc.Inventors: Jason Flora, Barbara K. Zedler, Edward Lenn Murrelle, Mark Leppert, Edwin J. C. G. van den Oord, Bradley Todd Webb, Timothy York, Gaurav S. J. B. Rana, Jeffrey S. Edmiston, Willie J. McKinney
-
Patent number: 9885085Abstract: Methods are disclosed for generating and isolating an informative content repository of respiratory related biomarkers to accurately determine whether an individual has normal or abnormal pulmonary function. Specifically, methods are directed to determination of whether individuals have chronic obstructive pulmonary disease, and if so, whether the affected individuals experience rapid long decline or slow lung decline as a result of COPD. Also disclosed is an informative content repository of chronic obstructive pulmonary disease biomarkers, which when linked with other informative content provides a powerful tool for diagnosis, study, therapeutic discovery and development, condition management, health maintenance, and linking chronic obstructive pulmonary disease through pattern of life style, environmental exposure, and genetic susceptibility and inheritance.Type: GrantFiled: June 28, 2007Date of Patent: February 6, 2018Assignees: University of Utah Research Foundation, Lineagen, Inc.Inventors: John Hoidal, Mary Beth Scholand, Mark F. Leppert, Michael S. Paul, Robert Mark Gritz, Joel Gardner Pounds, Richard Dale Smith
-
Publication number: 20180004895Abstract: The present invention relates to methods of detecting differentially expressed protein expression indicative of COPD in a test sample. The detection of circulating levels of proteins within an identified COPD biomarker signature can aid in COPD diagnosis and disease monitoring, as well as in the prediction of responses to therapeutics. Evaluation of the biomarker signatures disclosed, or a subset of biomarkers thereof, provides a level of discrimination not found with individual markers.Type: ApplicationFiled: July 14, 2017Publication date: January 4, 2018Applicant: Lineagen, Inc.Inventors: Francois Gervais, Viswanath Devanarayan
-
Patent number: 9823204Abstract: Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance (1H-NMR) spectroscopy is used in methods to identify metabolites and biomarkers associated with lung function in COPD.Type: GrantFiled: July 3, 2012Date of Patent: November 21, 2017Assignee: Lineagen, Inc.Inventors: Joseph Louie McClay, Barbara K. Zedler, Edward Lenn Murrelle, Edwin J. C. G. van den Oord, Thomas O'Connell, Daniel Adkins
-
Publication number: 20110160070Abstract: The present invention relates to methods of detecting differentially expressed protein expression indicative of COPD in a test sample. The detection of circulating levels of proteins within an identified COPD biomarker signature can aid in COPD diagnosis and disease monitoring, as well as in the prediction of responses to therapeutics. Evaluation of the biomarker signatures disclosed, or a subset of biomarkers thereof, provides a level of discrimination not found with individual markers.Type: ApplicationFiled: February 27, 2009Publication date: June 30, 2011Applicant: Lineagen, Inc.Inventors: Francois Gervais, Viswanath Devanarayan
-
Publication number: 20100210471Abstract: The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.Type: ApplicationFiled: November 12, 2009Publication date: August 19, 2010Applicants: University of Utah Research Foundation, LineaGen, Inc.Inventors: Mark F. Leppert, William McMahon, Nori Matsunami
-
Publication number: 20100167421Abstract: Methods and compositions for diagnosing multiple sclerosis (“MS”) in an individual or the predisposition or risk of MS, and for the prediction of the response to treatment of MS in an individual. More particularly, methods and compounds for the use of clinical, neuroradiological, genetic, biological and/or immunological markers as prognostic indicators, diagnostic markers, or predictors of response to MS therapy.Type: ApplicationFiled: September 21, 2009Publication date: July 1, 2010Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION, LINEAGEN, INC.Inventors: John W. Rose, Mark F. Leppert